Trial Profile
IMFINZI Injection 120 mg, 500 mg Specific-Clinical Experience Investigation in Patients With Locally Advanced Unresectable Non-small Cell Lung Cancer Who Are Treated With Maintenance Therapy After Definitive Chemoradiation Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Aug 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 13 Jul 2021 Status changed from active, no longer recruiting to completed.
- 03 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 06 Nov 2018 Status changed from not yet recruiting to recruiting.